electroCore, Inc. (ECOR)

[Polyphemus]

IMO, for FDA Breakthrough status to entice institutional investors prior to an strong uptick in numbers, CEO must (1) articulate a pivot from headache as primary focus to PTSD and provide some solid estimate of the serviceable market. (2) ECOR should be prepared to breakout sales by indication to show value of the indication and the ability of management team to execute on it. The lackluster performance of the past years raises questions about ability of ECOR to execute.

Look back at your post of Jan 15 in a month.